Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

482
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
482

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Bruton's tyrosine kinase inhibitors: a new class of multiple sclerosis therapeutics.

The Lancet. Neurology·2026
Same author

Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.

Lancet (London, England)·2026
Same author

Socioeconomic impact of depression and pain in patients with neuromyelitis optica spectrum disorders.

Neurological research and practice·2026
Same author

Glatiramer acetate stimulates phagocytosis and intracellular killing of <i>Escherichia coli</i> by macrophages and microglial cells.

Frontiers in immunology·2026
Same author

Microglia-associated progression of multiple sclerosis: target identification and therapeutic engagement in human in vitro models.

Experimental & molecular medicine·2026
Same author

Cellular and humoral vaccination response under immunotherapies-German consensus on vaccination strategies in neurological autoimmune diseases.

Therapeutic advances in neurological disorders·2025
Same journal

Correction: Jiménez-Sánchez et al. Antioxidant Enzymes Genetic Variants Associated with Urticaria/Angioedema Induced by Cross-Reactive Hypersensitivity to Nonsteroidal Anti-Inflammatory Drugs. <i>Pharmaceuticals</i> 2026, <i>19</i>, 522.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Correction: Zhao et al. Multifunctional Gel Films of Marine Polysaccharides Cross-Linked with Poly-Metal Ions for Wound Healing. <i>Pharmaceuticals</i> 2022, <i>15</i>, 750.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Intravenous Immunoglobulin Reveals a Novel Protective Mechanism: Targeting the GBP5-Driven Pyroptosis Axis in Experimental Colitis.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Icariin Attenuates Renal Injury in Streptozotocin-Induced Diabetic Rats with and Without Adenine-Induced Chronic Kidney Disease.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

AI-Assisted Identification of a Putative Allosteric Ligand Targeting the CDK4/Cyclin D1 Protein-Protein Interface.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Development and Study of Hydrophilic Ointment Compositions with a Dextrin/Polyvinyl Alcohol/Iodine Complex (D/PVA/I).

Pharmaceuticals (Basel, Switzerland)·2026
查看所有相关文章

相关实验视频

Updated: Jun 6, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

57.9K

为了治疗多发性硬化症,疾病的进展.

Darius Häusler1,2, Martin S Weber1,2,3

  • 1Institute of Neuropathology, University Medical Centre, 37075 Goettingen, Germany.

Pharmaceuticals (Basel, Switzerland)
|November 27, 2024
PubMed
概括
此摘要是机器生成的。

多发性硬化症 (MS) 涉及中枢神经系统的炎症和脱髓化. 目前的治疗方法可以控制复发,但对于渐进式多发性硬化症 (PMS) 治疗效果较差,这凸显了需要新的治疗策略.

关键词:
临床试验是指临床试验中的临床试验.分隔的炎症是分隔的炎症多发性硬化症多发性硬化症神经保护神经保护神经修复神经的修复这是一个渐进的过程.复兴再生是一种再生方式.复黄化是复黄化的一种.治疗疗法治疗疗法治疗疗法治疗治疗治疗治疗治疗治疗

更多相关视频

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.2K
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.0K

相关实验视频

Last Updated: Jun 6, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

57.9K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.2K
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.0K

科学领域:

  • 神经免疫学 神经免疫学
  • 神经学 神经学
  • 病理生理学 病理生理学

背景情况:

  • 多发性硬化症 (MS) 是中枢神经系统 (CNS) 的一种慢性炎症性脱髓化疾病.
  • 多发性硬化病理在复发复发和渐进阶段涉及不同的机制,包括中枢神经系统内在的过程.
  • 现有的疾病修饰疗法主要针对外周免疫,对复发比进展更有效.

研究的目的:

  • 审查MS进展背后的病理机制.
  • 总结目前对渐进性多发性硬化 (PMS) 的治疗策略.
  • 讨论新的PMS疗法的新兴治疗目标.

主要方法:

  • 对MS进展中的病理机制的审查.
  • 已批准和正在研究的PMS治疗方法的摘要.
  • 讨论潜在的未来治疗目标.

主要成果:

  • 多发性硬化症的进展涉及中枢神经系统内在的病理生理学,包括缓慢扩大的病变和大脑缩,这在疾病的早期开始.
  • 目前的多发性硬化症治疗有效减少复发,但在阻止疾病进展方面表现出有限的有效性.
  • 目前正在研究PMS的几种新治疗方案,针对不同的病理途径.

结论:

  • 了解MS进展的中枢神经系统内在机制对于开发有效的治疗方法至关重要.
  • 对于可以阻止或逆转渐进性多发性硬化症的疗法,存在着大量未满足的需求.
  • 未来的研究应该专注于解决PMS特定病理的新型治疗目标.